Canadian bioinformaticians develop new tools to create 3D structure of RNA.

American researchers may have run off with the big prizes in science this week, but finally there's some good news for dear old Orstralya - we won an Ig Nobel!

The power of array CGH to detect chromosomal losses and gains across the genome is sparking moves into clinical diagnostics, as Kate McDonald reports.

Astop Biohealth, an unlisted natural medicines company established in 2001 and chaired by Perth entrepreneur Kevin Parry, is planning to list on the ASX before the end of the year.

What causes those headaches that keep on thumping after you've exceeded your recommended daily allowance of garden-variety analgesics? A team at QIMR is close to finding out.

Melissa Trudinger looks at the issues that are set to arise as debate begins again on stem cell research in Australia.

Advocates and opponents of stem cell research across Australia are gearing up for the reignition of the debate that polarised Australia's state and federal governments in 2002.

"The right drug for the right patient at the right time" could be the motto of the Personalised Medicine Coalition (PMC), a non-profit group announced last week in Washington. The coalition, which includes members from industry, government, academia, and patient advocacy groups, aims to "foster understanding and adoption of personalised medicine for the benefit of patients."

The news from a pre-clinical trial of Perth biopharma Solbec Pharmaceuticals' (ASX:SBP) lead anti-cancer compound SBO002 could hardly be more positive.